scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript

John Tucker: There’ll be no impact unless change went for months here, right, which we don’t anticipate. I think anyone anticipates that, there’s no impact on how we’re looking at expanding the sales force at all. So I think what our thinking has been is that to expand it to 90 here midyear in front of the Class IV approval and then to 125 very early next year in front of the CKD expansion. That’s the thinking right now, but there will be no impact from Change Healthcare on that.

Naz Rahman: Once again, congrats on the progress.

John Tucker: Thanks, Naz. Appreciate it.

Operator: There are no further questions in the queue. I’d like to hand it back to management for closing remarks.

John Tucker: Great. Thank you very much. That concludes our call this afternoon. We remain pleased with the trajectory of our FUROSCIX launch, and we expect that the meaningful progress that we’re making with payers will add to our momentum. Its heart failure patients gain affordable access to FUROSCIX. We are excited about our life cycle initiatives after having directive discussions with the FDA and look forward to providing some updates as we progress through 2024. Overall, I’m pleased with our progress and believe that we can build on our current momentum and look forward towards a successful year. Thank you again, and have a great evening.

Operator: Ladies and gentlemen, this does conclude today’s teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.